In one paragraphArticle in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
34 authors.
Laura PolcikDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Abhishek PetheDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-8971-3490 Driti AshokDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0009-0003-5296-3271 Erika TissinoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.ORCID 0000-0001-6093-1649 Adrián Fernández-RegoDepartment of Immunology & Oncology, Centro Nacional de Biotecnología-Consejo Superior de Investigaciones Científicas, Madrid, Spain.ORCID 0009-0000-4938-9609 Federico PozzoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.ORCID 0000-0002-2986-7658 Danielle-Justine DannerDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Manuel HolstInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-2174-5314 Claudio MartinesMolecular Hematology Unit, International Center for Genetic Engineering and Biotechnology, Trieste, Italy.ORCID 0000-0001-7136-7174 Karin HofmannMolecular Hematology Unit, International Center for Genetic Engineering and Biotechnology, Trieste, Italy.
Aleksandar J DimovskiMacedonian Academy of Sciences and Arts, Skopje, North Macedonia.
Sandra KisselDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0009-0007-4714-2582 Andrea HärzschelDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Lixia LiDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Tamara BittoloClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.ORCID 0000-0003-3674-4362 Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-5389-9481 Theresa HaslauerDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria.ORCID 0000-0002-8331-0922 Jan Philip HöpnerDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria.ORCID 0009-0003-1788-1297 Nadja ZaborskyDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria.ORCID 0000-0002-9775-185X Richard GreilDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria.ORCID 0000-0002-4462-3694 Cornelius MiethingDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-4699-3805 Jesus Duque-AfonsoDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-8287-5673 Natalie KöhlerDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-7502-0431 Melanie BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-3670-0602 Riccardo BombenClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.ORCID 0000-0002-8746-9404 Justus DuysterDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-7325-7753 Robert GrosseInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-3380-5273 Gianluca GaidanoDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy.ORCID 0000-0002-4681-0151 Antonella ZucchettoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.ORCID 0000-0003-3678-5957 Yolanda R CarrascoDepartment of Immunology & Oncology, Centro Nacional de Biotecnología-Consejo Superior de Investigaciones Científicas, Madrid, Spain.ORCID 0000-0003-2148-1926 Dimitar G EfremovMolecular Hematology Unit, International Center for Genetic Engineering and Biotechnology, Trieste, Italy.ORCID 0000-0001-9081-5462 Valter GatteiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.ORCID 0000-0001-5933-9680 Tanja Nicole HartmannDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-0377-7179 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
abstractB-cell receptor (BCR) signaling is a key determinant of chronic lymphocytic leukemia (CLL) pathophysiology. CD49d, the α4 subunit of the very late antigen 4 integrin, can be activated by BCR signals; however, its role in modulating BCR functionality remains unknown. We used knockout mouse models and primary human CLL stratified by CD49d expression to address this aspect. CD49d was required for bone marrow (BM) infiltration and shaped BM infiltration patterns and patient outcomes in human CLL. In TCL1 transplantation models, the loss of CD49d abrogated BM homing and leukemic cell positioning within splenic niches. At the cellular level, CD49d-deficient murine TCL1 transgenic cells and human CD49d-low CLL cells failed to form efficient immune synapses with antigen-presenting membranes. Transcriptome analyses identified CD49d-dependent regulation of actin-associated pathways and distinct signatures of BCR responsiveness in both human and mouse cells. Consistently, CD49d-low human CLL cells displayed aberrant actin remodeling following BCR stimulation, and a second aggressive murine CLL model reproduced the actin and engraftment defects. Kinome profiling linked impaired antigen-induced BCR responses in CD49d-deficient murine cells to altered kinase activity, and pharmacologic actin perturbation phenocopied CD49d loss. In human CD49d-low CLL cells, a desynchronization of BCR-related downstream Syk and PLCɣ2 activation was found. Mechanistically, the CD49d-BCR interplay involved their colocalization, and CD49d converged with BCR signaling on a focal adhesion kinase-actin axis. In summary, our findings establish CD49d as a key regulator of BCR functionality in CLL, linking integrins to cytoskeletal dynamics and antigen responsiveness.
Indexed as
ActinsImmunological SynapsesIntegrin alpha4Leukemia, Lymphocytic, Chronic, B-CellReceptors, Antigen, B-CellSignal TransductionAnimalsHumansMiceMice, KnockoutSyk KinaseActinsIntegrin alpha4Receptors, Antigen, B-CellSyk Kinase
Identifiers
PMID41790574
PMCPMC13386099
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390